Tuen Mun Hospital | Department of Medicine and Geriatrics

Research site

(Unclaimed)

Location

23 Tsing Chung Koon Road, Hong Kong, Hong Kong, China

Site insights

Top conditions

Top treatments

Cisplatin

5-fluorouracil

Mycophenolate Mofetil

Tacrolimus

Pembrolizumab

Upadacitinib

Denosumab

Azacitidine

Magrolimab

Capecitabine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 54 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Upadacitinib

Drug: Upadacitinib

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling

Early Breast Cancer

Drug: Endocrine Therapy of Physician's Choice

Drug: Abemaciclib

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Crizotinib

Drug: Lorlatinib

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Risankizumab IV

Drug: Risankizumab SC

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab...

Enrolling

Metastatic Non Small Cell Lung Cancer

Drug: Carboplatin

Drug: Datopotamab Deruxtecan

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting

Breast Cancer

Drug: Standard Adjuvant Endocrine Therapy

Drug: Abemaciclib

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participan...

Active, not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Drug: NAH therapy

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

Locations recently updated

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults with Rheumatoid Arthritis (FINCH 4)

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the...

Active, not recruiting

Rheumatoid Arthritis

Drug: Filgotinib

Drug: Placebo to match filgotinib

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)

The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

Active, not recruiting

Nonmetastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Drug: Placebo

Drug: Enzalutamide

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Active, not recruiting

Triple Negative Breast Cancer

PD-L1 Positive

Drug: Pembrolizumab

Drug: Carboplatin

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling

Triple Negative Breast Cancer

PD-L1 Negative

Drug: Sacituzumab Govitecan-hziy

Drug: Paclitaxel

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants...

Active, not recruiting

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Drug: Carboplatin

Drug: Cisplatin